ClinicalTrials.gg
RecruitingNCT05234684BELIEVE-01Updated Feb 7, 2024

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

A Phase 3 interventional study of Orelabrutinib + R-CHOP and Placebo + R-CHOP in Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 44 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse — 9 open to participants now, 9 under way, 2 of them phase 3. orelabrutinib · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
3rd of 11
150 · median 39
Started
2022
with 2 others
Phase 3
2 of 11
2 open now
Registered
2nd of 11
by date
Lead sponsor
2 of 11
Beijing InnoCare Pharma Tech Co., Ltd.

Among the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2022, is one of 2 in phase 3, and was the 2nd registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

9 of the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP regimen versus placebo with R-CHOP in the treatment of treatment-naïve patients with MCD subtype DLBCL.

03

Conditions studied

  • Diffuse Large B Cell Lymphoma (DLBCL)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women between 18 and 80 years old
  2. Treatment-naive patients
  3. confirmed diffuse large B-cell lymphoma (DLBCL) and CD20 positive.
  4. Provide FFPE slices of past or fresh tumor tissue.
  5. At least one .
  6. Lymphoma International Prognostic Score (IPI) ≥ 2.
  7. Ann Arbor stage II-IV, or stage I with bulky lesion (diameter > 7.5 cm)
  8. PS score of 0-2
  9. Subjects who in line with the testing standard of the clinical trial laboratory.
  10. ≥ 6 months.
  11. Able to provide signed written .

Exclusion criteria

Exclusion Criteria:

  1. History of other active within 5 years of study entry, unless cured without evidence of relapse or
  2. Lymphoma involving the central nervous system or .
  3. Transformed lymphoma, that is transformed from other types of lymphoma.
  4. Primary mediastinal large B-cell lymphoma.
  5. History of stroke or intracranial hemorrhage within 6 months before screening.
  6. Co-morbidity of uncontrolled or significant cardiovascular disease, significant impaired lung function, significant gastrointestinal abnormalities, uncontrolled infections (including , , /AIDS and tuberculosis), or active disease.
  7. Active bleeding within 2 months before screening, or a clear bleeding tendency determined by the investigator; a history of deep vein thrombosis or pulmonary embolism.
  8. Previous history of surgeries (major 4 weeks and minor 2 weeks prior screening) , organ transplant or hematopoietic stem cell transplantation, or progressive multifocal leukoencephalopathy (PML).
  9. Administer live and attenuated vaccines (semi-inactivated) within 28 days prior to first receiving the test drug.
  10. Planned stem cell transplant during the experimental treatment are excluded.
  11. Chemotherapy, immunotherapy, targeted therapy, radiotherapy, or traditional Chinese medicine with anti-tumor effects for the purpose of anti-tumor therapy within 4 weeks before starting to take the experimental drug. Excluding short-term emergency use of before treatment.
  12. Current diagnosis of any mental or cognitive impairment, drug abuse, or alcohol abuse.
  13. Pregnant, lactating women, or women at childbearing ages who will not use during the study up to 12 months after the last dose of rituximab or 180 days after the last dose of study drug
  14. The last use of strong inhibitor or strong CYP3A inducer is less than 5 halflivesfrom the first trial drug, or the drug or food with moderate and strong CYP3A inhibitory effect or strong CYP3A induction effect is planned to be taken at the same time during this study.
  15. Any serious medical condition that, in the investigator's opinion, would put the subject at unacceptable risk and/or would prevent the subject from signing the form. In the opinion of the investigator, the subject's participation in the study would be at unacceptable risk.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Orelabrutinib+ R-CHOP

    Participants will receive 150 mg of oral orelabrutinib once daily with R-CHOP on day 1 of each cycle (21 days).

    Drug: Orelabrutinib + R-CHOP

  • Placebo comparator
    Placebo+ R-CHOP

    Participants will receive 150 mg placebo once daily with R-CHOP on day 1 of each cycle (21 days).

    Drug: Placebo + R-CHOP

Interventions

  • DrugOrelabrutinib + R-CHOP

    Drug page: Orelabrutinib

    The orelabrutinib is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.

    Also known as: ICP-022+ R-CHOP

  • DrugPlacebo + R-CHOP

    The placebo is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    Progression free survival (PFS) accessed by independent review committee (IRC)

    Time frame: Up to 3 years and 9 months

  2. Complete response rate (CRR) by independent review committee (IRC)

    Complete response rate (CRR) at the completion of combination therapy accessed by independent review committee (IRC)

    Time frame: Up to 3 years and 9 months

Secondary outcomes

  1. Complete response rate (CRR) by investigator

    Complete response rate (CRR) at the completion of combination therapy accessed by investigator

    Time frame: Up to 3 years and 9 months

  2. Overall response rate (ORR) by independent review committee (IRC) and investigator

    Overall response rate (ORR) accessed by independent review committee (IRC) and investigator

    Time frame: Up to 3 years and 9 months

  3. Overall response rate (ORR) at the completion of combination therapy by independent review committee (IRC) and investigator

    Overall response rate (ORR) at the completion of combination therapy accessed by independent review committee (IRC) and investigator

    Time frame: Up to 3 years and 9 months

  4. Duration of Response (DOR)

    Duration of Response (DOR) accessed by independent review committee (IRC) and investigator

    Time frame: Up to 3 years and 9 months

  5. Disease free survival (DFS) rate and event free survival (EFS) rate

    2-year disease free survival (DFS) rate and 2-year event free survival (EFS) rate

    Time frame: Up to 2 years

  6. Overall survival (OS) rate

    2-year overall survival (OS) rate Accessed by independent review committee (IRC) and investigator

    Time frame: Up to 2 years

  7. Occurrence of adverse events and serious adverse events according to CTCAE V5.0.

    The safety of Orelabrutinib measured by the occurrence of adverse events and serious adverse events according to CTCAE V5.0.

    Time frame: Up to 3 years and 9 months

07

Study locations

40 of 44 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jul 2024, 20 months after the start.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's planned 20 months is below that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2022
First posted
Feb 10, 2022
StartActual
Nov 2, 2022
Primary completionEst.
Jul 30, 2024
CompletionEst.
Dec 30, 2025
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05234684
Responsible party
Sponsor
First posted
Feb 10, 2022
Start date
Nov 2, 2022
Primary completion
Jul 30, 2024 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Feb 7, 2024

Study contacts

Weili Zhao
Contact
zwl_trial@163.com
+86 021-64370045
Weili Zhao
principal investigator · Ruijin Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion